Jianpi Yiqi Busui prescription alleviates myasthenia gravis by regulating Th17 through the TAK1/P38 MAPK/eIF-4E signaling pathway
Jianpi Yiqi Busui Prescription (JYBP), a traditional Chinese medicine (TCM) formula, is used in the treatment of myasthenia gravis (MG). However, its mechanisms of action still require further clarification. In this study, an experimental autoimmune myasthenia gravis (EAMG) rat model was establishe...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
2025-02-01
|
| Series: | Biomolecules & Biomedicine |
| Subjects: | |
| Online Access: | https://bjbms.org/ojs/index.php/bjbms/article/view/11546 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864945930928128 |
|---|---|
| author | Zhuming Chen Jing Lu Tianying Chang Dongmei Zhang Yibin Zhang Miao Liu Tong Wu Peng Xv Jian Wang |
| author_facet | Zhuming Chen Jing Lu Tianying Chang Dongmei Zhang Yibin Zhang Miao Liu Tong Wu Peng Xv Jian Wang |
| author_sort | Zhuming Chen |
| collection | DOAJ |
| description |
Jianpi Yiqi Busui Prescription (JYBP), a traditional Chinese medicine (TCM) formula, is used in the treatment of myasthenia gravis (MG). However, its mechanisms of action still require further clarification. In this study, an experimental autoimmune myasthenia gravis (EAMG) rat model was established for research. Changes in body weight, forelimb grip strength, Lennon clinical score, and antifatigue ability of EAMG model rats were recorded to evaluate the effectiveness of JYBP. Flow cytometry was utilized to count Th17, Th1, Th2, and Treg cells in lymphocytes. ELISA and RT-qPCR were used to measure acetylcholine receptor antibody (AChR-Ab) and Th17-related cytokines, including IL-17, IL-21, IL-23, TNF-α, TGF-β, IL-1β, and IL-6. Western blot and immunofluorescence staining were used to detect the expression levels of key proteins and their phosphorylated forms, such as transforming growth factor beta-activated kinase 1 (TAK1), P38 mitogen-activated protein kinase (P38 MAPK), and eukaryotic initiation factor 4E (eIF-4E). The results indicate that JYBP can increase the body weight of EAMG model rats, improve grip strength and antifatigue ability, and reduce the Lennon clinical score and AChR-Ab concentration. Mechanistic studies indicate that JYBP can inhibit the differentiation of CD4+ T cells into Th17 and Th1, promote their differentiation into Th2 and Treg, and regulate the expression of Th17-related cytokines. Further research shows that JYBP can reduce the expression of related proteins in the TAK1/P38 MAPK/eIF-4E signaling pathway. In conclusion, JYBP can alleviate the condition of EAMG model rats, positively affecting MG treatment. The inhibitory effect of JYBP on the differentiation of CD4+ T cells into Th17 may be related to the TAK1/P38 MAPK/eIF-4E signaling pathway.
|
| format | Article |
| id | doaj-art-e74297d67ecd4544a6c9930ca68b3dc7 |
| institution | Kabale University |
| issn | 2831-0896 2831-090X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
| record_format | Article |
| series | Biomolecules & Biomedicine |
| spelling | doaj-art-e74297d67ecd4544a6c9930ca68b3dc72025-02-08T16:42:39ZengAssociation of Basic Medical Sciences of Federation of Bosnia and HerzegovinaBiomolecules & Biomedicine2831-08962831-090X2025-02-0110.17305/bb.2025.11546Jianpi Yiqi Busui prescription alleviates myasthenia gravis by regulating Th17 through the TAK1/P38 MAPK/eIF-4E signaling pathwayZhuming Chen0https://orcid.org/0000-0002-6129-0043Jing Lu1https://orcid.org/0000-0002-7725-1591Tianying Chang2https://orcid.org/0000-0003-2040-5147Dongmei Zhang3Yibin Zhang4Miao Liu5https://orcid.org/0000-0002-6326-6311Tong Wu6https://orcid.org/0000-0003-4279-9327Peng Xv7Jian Wang8https://orcid.org/0000-0003-1748-7305College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Neurology, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China; Research Center of Traditional Chinese Medicine, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Neurology, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China; Evidence-based Office, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Neurology, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaCollege of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, ChinaCollege of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, ChinaCollege of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Neurology, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, ChinaDepartment of Neurology, The Affiliated Hospital to Changchun University of Chinese Medicine, Changchun, China Jianpi Yiqi Busui Prescription (JYBP), a traditional Chinese medicine (TCM) formula, is used in the treatment of myasthenia gravis (MG). However, its mechanisms of action still require further clarification. In this study, an experimental autoimmune myasthenia gravis (EAMG) rat model was established for research. Changes in body weight, forelimb grip strength, Lennon clinical score, and antifatigue ability of EAMG model rats were recorded to evaluate the effectiveness of JYBP. Flow cytometry was utilized to count Th17, Th1, Th2, and Treg cells in lymphocytes. ELISA and RT-qPCR were used to measure acetylcholine receptor antibody (AChR-Ab) and Th17-related cytokines, including IL-17, IL-21, IL-23, TNF-α, TGF-β, IL-1β, and IL-6. Western blot and immunofluorescence staining were used to detect the expression levels of key proteins and their phosphorylated forms, such as transforming growth factor beta-activated kinase 1 (TAK1), P38 mitogen-activated protein kinase (P38 MAPK), and eukaryotic initiation factor 4E (eIF-4E). The results indicate that JYBP can increase the body weight of EAMG model rats, improve grip strength and antifatigue ability, and reduce the Lennon clinical score and AChR-Ab concentration. Mechanistic studies indicate that JYBP can inhibit the differentiation of CD4+ T cells into Th17 and Th1, promote their differentiation into Th2 and Treg, and regulate the expression of Th17-related cytokines. Further research shows that JYBP can reduce the expression of related proteins in the TAK1/P38 MAPK/eIF-4E signaling pathway. In conclusion, JYBP can alleviate the condition of EAMG model rats, positively affecting MG treatment. The inhibitory effect of JYBP on the differentiation of CD4+ T cells into Th17 may be related to the TAK1/P38 MAPK/eIF-4E signaling pathway. https://bjbms.org/ojs/index.php/bjbms/article/view/11546Myasthenia gravisMGtraditional Chinese medicineTCMJianpi Yiqi Busui prescriptionJYBP |
| spellingShingle | Zhuming Chen Jing Lu Tianying Chang Dongmei Zhang Yibin Zhang Miao Liu Tong Wu Peng Xv Jian Wang Jianpi Yiqi Busui prescription alleviates myasthenia gravis by regulating Th17 through the TAK1/P38 MAPK/eIF-4E signaling pathway Biomolecules & Biomedicine Myasthenia gravis MG traditional Chinese medicine TCM Jianpi Yiqi Busui prescription JYBP |
| title | Jianpi Yiqi Busui prescription alleviates myasthenia gravis by regulating Th17 through the TAK1/P38 MAPK/eIF-4E signaling pathway |
| title_full | Jianpi Yiqi Busui prescription alleviates myasthenia gravis by regulating Th17 through the TAK1/P38 MAPK/eIF-4E signaling pathway |
| title_fullStr | Jianpi Yiqi Busui prescription alleviates myasthenia gravis by regulating Th17 through the TAK1/P38 MAPK/eIF-4E signaling pathway |
| title_full_unstemmed | Jianpi Yiqi Busui prescription alleviates myasthenia gravis by regulating Th17 through the TAK1/P38 MAPK/eIF-4E signaling pathway |
| title_short | Jianpi Yiqi Busui prescription alleviates myasthenia gravis by regulating Th17 through the TAK1/P38 MAPK/eIF-4E signaling pathway |
| title_sort | jianpi yiqi busui prescription alleviates myasthenia gravis by regulating th17 through the tak1 p38 mapk eif 4e signaling pathway |
| topic | Myasthenia gravis MG traditional Chinese medicine TCM Jianpi Yiqi Busui prescription JYBP |
| url | https://bjbms.org/ojs/index.php/bjbms/article/view/11546 |
| work_keys_str_mv | AT zhumingchen jianpiyiqibusuiprescriptionalleviatesmyastheniagravisbyregulatingth17throughthetak1p38mapkeif4esignalingpathway AT jinglu jianpiyiqibusuiprescriptionalleviatesmyastheniagravisbyregulatingth17throughthetak1p38mapkeif4esignalingpathway AT tianyingchang jianpiyiqibusuiprescriptionalleviatesmyastheniagravisbyregulatingth17throughthetak1p38mapkeif4esignalingpathway AT dongmeizhang jianpiyiqibusuiprescriptionalleviatesmyastheniagravisbyregulatingth17throughthetak1p38mapkeif4esignalingpathway AT yibinzhang jianpiyiqibusuiprescriptionalleviatesmyastheniagravisbyregulatingth17throughthetak1p38mapkeif4esignalingpathway AT miaoliu jianpiyiqibusuiprescriptionalleviatesmyastheniagravisbyregulatingth17throughthetak1p38mapkeif4esignalingpathway AT tongwu jianpiyiqibusuiprescriptionalleviatesmyastheniagravisbyregulatingth17throughthetak1p38mapkeif4esignalingpathway AT pengxv jianpiyiqibusuiprescriptionalleviatesmyastheniagravisbyregulatingth17throughthetak1p38mapkeif4esignalingpathway AT jianwang jianpiyiqibusuiprescriptionalleviatesmyastheniagravisbyregulatingth17throughthetak1p38mapkeif4esignalingpathway |